Related Experiment Video

Updated: Jun 22, 2026

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase
09:51

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase

Published on: June 30, 2023

Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer

Teresa A Soucy1, Peter G Smith, Mark Rolfe

  • 1Discovery, Millennium Pharmaceuticals, Inc, Cambridge, Massachusetts 02139, USA. teresa.soucy@mpi.com

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 11, 2009
PubMed

Insights

Targeting NEDD8-activating enzyme (NAE) offers a novel strategy against cancer by inhibiting cullin-RING ubiquitin E3 ligases (CRLs). A first-in-class NAE inhibitor is in clinical trials for various cancers.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • E3 ubiquitin ligases are crucial regulators of cellular processes and cancer cell survival.
  • The ubiquitin-proteasome system is a validated therapeutic target, as demonstrated by bortezomib.
  • Cullin-RING ubiquitin E3 ligases (CRLs) are the largest subfamily of E3s, essential for cancer cell function.

Purpose of the Study:

  • To explore the role of the NEDD8 pathway in activating CRLs.
  • To discuss preclinical findings of a novel NEDD8-activating enzyme (NAE) inhibitor.
  • To evaluate the potential clinical utility of NAE inhibitors in cancer treatment.

Main Methods:

  • Investigated the mechanism of CRL activation via NEDD8 modification.
  • Reviewed preclinical data of a first-in-class NAE inhibitor.
  • Analyzed the role of NAE in the context of cancer cell survival.

Main Results:

  • NAE catalyzes the initial step in the NEDD8 pathway, controlling CRL activity.
  • A first-in-class NAE inhibitor has shown promise in preclinical studies.
  • This NAE inhibitor is currently undergoing Phase I clinical trials for solid and hematological malignancies.

Conclusions:

  • Targeting NAE presents a "Achilles heel" for modulating the CRL subfamily.
  • NAE inhibitors represent a promising therapeutic strategy for various cancer types.
  • Further clinical investigation is warranted to establish the efficacy of NAE inhibitors.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...